Mark Masin
Impact in
- Immunology top 10%
- IL-33, ST2, and ILC Pathways
- Immune Response and Inflammation
- Immune Cell Function and Interaction
-
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Protein Degradation and Inhibitors 3
- RNA modifications and cancer 2
- Inflammasome and immune disorders 2
- Metabolism, Diabetes, and Cancer 1
- Oncology 3
- Cancer Treatment and Pharmacology 1
- Co-authors
- Amir S. Yazdi (2 shared papers)Olaf Groß (2 shared papers)Stefan K. Drexler (2 shared papers)Jürg Tschopp (2 shared papers)Manfredo Quadroni (1 shared paper)Christina J. Thomas (1 shared paper)Greta Guarda (1 shared paper)Leonhard X. Heinz (1 shared paper)
- Journals
- PLoS Pathogens (2 papers)Immunity (1 paper)British Journal of Clinical Pharmacology (1 paper)Proceedings of the National Academy of Sciences (1 paper)Blood (1 paper)
- Partner nations
- SwitzerlandUnited StatesGermany
In The Last Decade
Mark Masin
9 papers receiving 782 citations
Peers
Comparison fields: 5 of 77
- Immunology 306
- Cancer Research 115
- Molecular Biology 500
- Nephrology 46
- Infectious Diseases 106
Countries citing papers authored by Mark Masin
This map shows the geographic impact of Mark Masin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Masin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Masin more than expected).
Fields of papers citing papers by Mark Masin
This network shows the impact of papers produced by Mark Masin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Masin. The network helps show where Mark Masin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Masin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 378 | |
| 2 | 2011 | 126 | |
| 3 | 2014 | 124 | |
| 4 | 2012 | 119 | |
| 5 | 2011 | 24 | |
| 6 | 2022 | 9 | |
| 7 | 2022 | 6 | |
| 8 | 2023 | 2 | |
| 9 | GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer | 2014 | 1 |
About Mark Masin
Mark Masin is a scholar working on Molecular Biology, Oncology, Hematology, Infectious Diseases and Nephrology, having authored 9 papers that have together received 789 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (3 papers), Multiple Myeloma Research and Treatments (3 papers), RNA modifications and cancer (2 papers), Inflammasome and immune disorders (2 papers), Viral Infections and Outbreaks Research (2 papers), Viral Infections and Vectors (2 papers), Cancer Treatment and Pharmacology (1 paper) and Metabolism, Diabetes, and Cancer (1 paper). The work is most often cited by research in Immunology (306 citations), Cancer Research (115 citations), Molecular Biology (500 citations), Nephrology (46 citations) and Infectious Diseases (106 citations). Mark Masin has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Amir S. Yazdi, Olaf Groß, Stefan K. Drexler, Jürg Tschopp, Manfredo Quadroni, Christina J. Thomas, Greta Guarda, Leonhard X. Heinz, Stefan Kunz and Giulia Pasqual. Their work appears in journals such as PLoS Pathogens, Immunity, British Journal of Clinical Pharmacology, Proceedings of the National Academy of Sciences and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.